<DOC>
	<DOCNO>NCT00406575</DOCNO>
	<brief_summary>Two dos relaxin compare placebo treatment patient decompensated CHF</brief_summary>
	<brief_title>Recombinant Human Relaxin Treatment Decompensated CHF</brief_title>
	<detailed_description>Pilot clinical data suggest recombinant human relaxin may effective treat patient decompensated CHF . This study randomize patient blind manner one two dos intravenous relaxin placebo . Serial evaluation include cardiac renal function , well safety tolerability .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Methocarbamol</mesh_term>
	<criteria>Hospitalization Decompensated chronic CHF ( NYHA Class IIIIV ) LVEF &lt; 35 % PCWP &gt; 22 mmHg CI &lt; 2.3 L/min/m2 Acute CHF Acute coronary syndrome Hypotension shock Recent stroke Allergy sensitivity test agent Significant confounding condition medication</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Congestive heart failure</keyword>
	<keyword>Relaxin</keyword>
	<keyword>Hemodynamics</keyword>
	<keyword>Renal function</keyword>
</DOC>